excluded from the analysis if any of the ASTRAL score components were not available or if admitted later than 24 hours after symptom onset (or last proof of good health in case of unknown onset stroke).
All patients were examined at admission by a stroke physician. Stroke severity was assessed with the National Health Institute Stroke Scale Score (NIHSS). All patients were treated according to current guidelines. Stroke pathogenesis was classified according to the Trial of Org 10172 in Acute Stroke Treatment criteria. 13 Cerebrovascular risk factors and previous evidence of cardiovascular disease were recorded using previously described definitions. 12, 14 ASTRAL score was calculated on the basis of age (1 point for every 5 years), severity (1 point for every admission NIHSS point), time delay between symptom onset or last proof of good health (in case of unknown onset stroke) and admission (2 points if >3 hours), presence of any new visual field defect (2 points), glucose at admission (1 point if >7.3 or <3.7 mmol/L), and level of consciousness (3 points if impaired). 9 The estimation of the presence of visual field defect was based on the third item of the NIHSS, whereas level of consciousness was judged from item 1a on the NIHSS.
All patients or one of their relatives provided written informed consent for inclusion in this registry. The Institutional Ethics Committee approved the scientific use of the data contained in the database.
Follow-up and Outcome Assessment
Patients were followed up prospectively at 1, 3, 6, and 12 months after discharge and yearly thereafter. Follow-up was routinely performed in the outpatient clinic by physicians. In case of patients with severe handicap who were not able to attend the outpatient clinic, follow-up was assessed by a telephone interview or at the patient's residence. Patient records, information from general practitioners, family physician's records, and death certificates were used to register death and define its cause. The end points of the study were unfavorable functional outcome-defined as modified Rankin Scale (mRS) >2-and overall mortality at 5 years.
Statistical Analysis
To investigate the prognostic value of the ASTRAL score to predict 5-year functional outcome and overall mortality, we assessed the discriminatory power of the score (ie, the degree to which the prognostic score enables the discrimination between patients with favorable and unfavorable outcome by calculating the area under the receiver operating characteristics curve [AUC]).
To further assess whether the ASTRAL score is an independent predictor of 5-year functional outcome and mortality, univariate Cox proportional hazard analyses were performed. ASTRAL score (as a continuous covariate), sex, arterial hypertension, diabetes mellitus, smoking, coronary artery disease, atrial fibrillation, dyslipidemia, heart failure, peripheral artery disease, valvular heart disease, systolic and diastolic blood pressure at admission (as a continuous covariate), and Trial of Org 10172 in Acute Stroke Treatment category were included in the analysis. For each outcome, a second analysis was performed analyzing ASTRAL score as a categorical covariate stratified into quartiles. Thrombolysis was not included as a covariate because of the small number of thrombolysed patients in the cohort. Those covariates which were found to be associated with outcome in the univariate analysis at a P=0.1 level (to minimize the risk of type II errors) were included in the multivariate Cox proportional hazard analyses. Associations are presented as hazard ratios (HRs) with 95% confidence intervals (CIs). In the multivariate analyses, the level of statistical significance was set at 95% (P=0.05).
In order to further investigate the association between the ASTRAL score and survival, the Kaplan-Meier product limit method was used to estimate the probability of 5-year survival for each ASTRAL quartile; the log-rank test was used to compare the probability of survival between the quartiles. For patients lost during follow-up, survival data were censored at the last date they were known to be alive.
For continuous variables, data are summarized as medians and interquartile range. Categorical data are presented as absolute numbers and percentage. The χ 2 test was used to compare dichotomous or categorical variables; continuous variables were compared with the ANOVA test.
All statistical analyses were performed with the Statistical Package for Social Science version 15.0 for Windows (SPSS Inc, Chicago, IL).
Results
From the entire cohort of 1701 patients with first-ever ischemic stroke, 42 (2.5%) were excluded because ≥1 of the 6 covariates of the ASTRAL score were unavailable. Among these 42 patients, age, NIHSS on admission, and level of consciousness were recorded in all patients. Four patients had missing glucose values, 7 had missing visual field evaluation data, 5 had missing onset to admission time, and in 26 patients >1 component of the ASTRAL score were missing. Also, 139 patients (8.1%) were excluded because of admission delay of >24 hours after the onset of symptoms or last proof of good health. Finally, 1520 patients (median age, 72 years; interquartile range, 63-78; 955 men [62.8%]) were included in the analysis. The baseline characteristics of the patients are summarized in Table 1 .
The AUC for ASTRAL score's discriminatory power to predict 5-year unfavorable functional outcome was 0.89 (95% CI, 0.88-0.91; Figure I The AUC for the ASTRAL score's discriminatory power to predict 5-year mortality was 0.81 (95% CI, 0.78-0.83; Figure II in online-only Data Supplement). In multivariate Cox analysis, the ASTRAL score (analyzed as a continuous covariate) was independently associated with 5-year mortality (HR, 1.09; 95% CI, 1.08-1.10; Table 2 During the 5-year follow-up period, the probability of survival was significantly lower with increasing ASTRAL score quartiles (log-rank test <0.001; Figure) . Mean survival was 57. 4 
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Discussion
The ASTRAL score was originally developed and externally validated to predict 3-month functional outcome after acute ischemic stroke. 9 The present study aimed to investigate whether the ASTRAL score can predict reliably disability and a hard end point (ie, mortality) in the long term (ie, 5 years). The results showed that the score can be used reliably to predict 5-year functional outcome and mortality, thus extending its applicability. To our knowledge, no prognostic model has been previously validated for the prediction of stroke outcome in such a long-run. [4] [5] [6] [7] [8] [15] [16] [17] [18] [19] [20] The ASTRAL score is the first prognostic score validated to predict stroke outcome >12 months. [4] [5] [6] [7] [8] [15] [16] [17] [18] [19] [20] The combination of speed (rapid calculation within minutes after emergency department arrival), simplicity and reliability in long-term prediction of a frequently used clinical end point (independence using the mRS), and mortality highlight the role the ASTRAL score as a valuable clinical and research tool.
Several prognostic scores have been introduced to predict stroke outcome, such as the score by Weimar et al, 4 the score by Counsell et al 5 (the Six Simple Variable score), the Bologna Outcome Algorithm for Stroke scale, 6 the iScore, 8 the PLAN score, 10 and the Get With the Guidelines risk model. 21 Among them, the only scores that were validated to predict stroke mortality in the long term are the PLAN score, the iScore, and the Six Simple Variable score 11 ; however, in all 3 cases, this was limited to 12-month follow-up. The PLAN score incorporates 9 clinical variables (ie, preadmission dependence, cancer, congestive heart failure, atrial fibrillation, level of consciousness, age, significant/total weakness of the leg, weakness of the arm, and aphasia/neglect) and was shown to predict 12-month stroke mortality reliably (AUC 0.84). However, it has only been validated internally and not externally. 10 The iScore was initially introduced for the prediction of 12-month stroke mortality and was later validated to predict also disability (mRS=3-5) or institutionalization at discharge, 18 and clinical response and risk of hemorrhagic complications after stroke thrombolysis. 22, 23 Compared with the iScore's discriminatory power of 12-month mortality in the Ontario Stroke Audit (AUC 0.78), 8 the ASTRAL score performed at least similarly to predict 5-year mortality (AUC 0.81). A caveat for the iScore is the need for recalibration/validation in other specific populations. 8 The Six Simple Variable score includes 6 simple variables (age, living alone before stroke, prestroke mRS≤2, normal verbal component of the Glascow Coma Scale, ability to lift both arms, and ability to walk without help) and at 12 performed, as well as or better than other simple predictive systems for the prediction of 12-month outcome. 11 The strengths of our study are the large size of the validation cohort, the hard end points, the long follow-up, and the confirmation of the results using several analytic methodologies. On the contrary, the study is limited by the fact that it is a single-center study and that only patients with first-ever stroke were included. Also, for a proportion of patients, mRS was assessed during a telephone interview and not in person; however, it was previously shown that telephone assessment of mRS is reliable and can be used in clinical studies. 24, 25 Finally, it is surprising that both atrial fibrillation and cardioembolic stroke remain in the multivariate model as independent predictors of unfavorable outcome. Given the borderline significance of the atrial fibrillation (95% CI, 1.03-2.63), it could be possible that this represents a type I statistical error (false-positive result).
In conclusion, the ASTRAL is a simple score available immediately after emergency department arrival that reliably predicts 5-year functional outcome and mortality in patients with first-ever stroke. Further validation of the ASTRAL score in other cohorts would be welcome.
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